BEXMAB
A Phase I/II Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of the Clever-1 Antibody Bexmarilimab in Combination With Standard of Care Therapy in Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia or Acute Myeloid Leukemia
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 181 patients (estimated)
- Sponsors
- Faron Pharmaceuticals Ltd
- Tags
- BCL-2 Inhibitor, Monoclonal Antibody, Clever-1
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1753
- NCT Identifier
- NCT05428969
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.